Promising immunotherapy combo takes on advanced liver cancer
NCT ID NCT04523493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding the immunotherapy drug toripalimab to the standard targeted therapy lenvatinib helps people with advanced liver cancer live longer. About 530 participants will receive either the combination or a placebo plus lenvatinib. The study is double-blind, meaning neither patients nor doctors know who gets the extra drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (an immunotherapy drug) combined with lenvatinib (a targeted therapy drug)
What this could lead to
If successful, this combination could become a new standard first-line treatment for advanced liver cancer, potentially extending survival.
What could go wrong
This is an early-stage Phase 3 trial; results may not confirm benefit. Immunotherapy can cause serious immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Citta della Salute e della Scienza di Torino
Tortona, Italy
-
AOUI Verona - Policlinico "G.B. Rossi" di Borgo Roma
Verona, 37134, Italy
-
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126, Italy
-
Centrum Medyczne Pratia Poznań
Skórzewo, 60-185, Poland
-
Communal Enterprise Volyn Regional Clinical Hospital of Volyn Regional Council
Lutsk, 43018, Ukraine
-
Communal Non-Profit Institution of Kharkiv Regional Council Regional Clinical Specialized Dispensary of Radiation Protection of Population
Kharkiv, 61166, Ukraine
-
Communal Non-commercial Enterprise City Clinical Hospital #4 of Dnipro City Council, Department of Chemotherapy
Dnipro, 49102, Ukraine
-
Communal Non-commercial Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Department of General Surgery
Odesa, 65025, Ukraine
-
Communal Non-commercial Enterprise Zaporizhzhia Regional Antitumor Center of Zaporizhzhia Regional Council
Zaporizhzhia, 69040, Ukraine
-
Communal Non-commercial Enterprise of Sumy Regional Council, Sumy Regional Clinical Oncological Dispensar
Sumy, 40022, Ukraine
-
Communal Non-profit Enterprise "Regional Center of Oncology", Department of Abdominal Organs Oncosurgery
Kharkiv, 61070, Ukraine
-
Copernicus Podmiot Leczniczy sp. z o.o., Wojewodzkie Centrum Onkologii, Oddzial Onkologii Klinicznej/Chemioterapii
Gdansk, 80-219, Poland
-
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico,Oncologia Medica
Milan, 20122, Italy
-
ID Clinic
Mysłowice, 41-400, Poland
-
IRCCS Fondazione Giovanni Pascale, Istituto Nazionale Dei Tumori
Naples, 80131, Italy
-
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Klinika Onkologii i Radioterapii
Warsaw, 02-034, Poland
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
PRATIA MCM Kraków, ul. Pana Tadeusza 2,
Krakow, 30-727, Poland
-
Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command
Nanjing, Jiangsu, 21000, China
-
State Inst. O.O.Shalimov Nat. scientific certer of Surgery and Transplantology of Nat. Academy of Med.Sciences of Ukraine, Dep.of Oncology
Kyiv, 03126, Ukraine
-
Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie, Oddzial Dzienny Chemioterapii
Koszalin, 75-581, Poland
-
Wielkopolskie Centrum Onkologii, Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dziennym i Izbą Przyjęć
Poznan, 61-866, Poland